CTLA4 and neoplasm: The use of molecules that block inhibitory signals, trigger co-stimulatory signals in combination with the stimulation of TLRs was shown by Marabelle et al. [101] who injected a TLR9 agonist (CpG nucleotides) together with anti-CTLA-4 or anti-OX40 antibodies intratumorally to deplete tumor-resident Tregs.